Navigation Links
Arete Therapeutics Appoints Donald Santel to Board of Directors
Date:12/6/2007

HAYWARD, Calif., Dec. 6 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class small molecule therapeutics for the treatment of cardiovascular, inflammatory and metabolic diseases, today announced the appointment of Donald J. Santel to its board of directors.

"We are very pleased to welcome Don to our board of directors, as his strategic and operational insights will be of great benefit to the Company as we advance our first-in-class antihypertensive agent AR9281 toward a clinical proof of concept," said Dinesh V. Patel, Ph.D., president and chief executive officer of Arete Therapeutics.

"Don's broad experience coupled with his understanding of the opportunities and challenges in building innovative healthcare organizations make him a valuable addition to the board of directors," said James Topper, M.D., Ph.D., chairman of the board of Arete Therapeutics.

Donald J. Santel brings more than 25 years experience in the biotechnology/biopharmaceutical and medical device industries. Most recently, he was co-founder and chief executive officer at CoTherix, Inc., where he launched Ventavis(R) Inhalation Solution and led the sale of the company to Actelion Pharmaceuticals, Ltd. in January 2007. Prior to CoTherix, he served as president and chief operating officer of Reflow, and sold the company to Fox Hollow (now EV3) and served as vice president of marketing and international sales at Cardiac Pathways Corporation, a medical device company later acquired by Boston Scientific. Mr. Santel began his career at Medtronic, Inc. Currently, Mr. Santel also serves on the board of Anthera Pharmaceuticals, ChemGenex Pharmaceuticals, and Hyperion Therapeutics. He has a BSE from Purdue University and an MS in from the University of Minnesota.

About Arete Therapeutics Inc.

Arete Therapeutics Inc. is a privately held pharmaceutical Company discovering and developing first-in-class small molecule drugs directed at soluble epoxide hydrolase (s-EH), a novel target for cardiovascular, metabolic and inflammatory diseases. By targeting s-EH which plays a key role in the arachidonic acid pathway, the Company is addressing the very large market need for a unique anti-hypertensive drug with renal sparing, cardio-protective and anti-inflammatory properties. Arete has discovered and developed a series of proprietary and chemically diverse molecules with preclinical efficacy in various animal models of hypertension, metabolic syndrome, and inflammation, and is conducting a phase 1 clinical trial with its first-in-class antihypertensive drug AR9281. The Company has raised a total of $51 million in Series A financing led by Frazier Healthcare Ventures (http://www.frazierhealthcare.com), Alta Partners (http://www.altapartners.com), Three Arch Partners (http://www.threearchpartners.com), Burrill & Company (http://www.burrillandco.com) and Altitude Life Science Ventures (http://www.altitudefunds.com). For more information on Arete Therapeutics, please visit http://www.aretetherapeutics.com.


'/>"/>
SOURCE Arete Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
2. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
3. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
4. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
5. Prime Therapeutics Receives TIPPS Certification
6. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
7. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
8. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
9. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 06, 2016 , ... In honor of Military Spouse Appreciation ... and the National Military Family Association, a nonprofit that works to strengthen and ... scholarship recipient of 2016. , “Being awarded this scholarship by Career Step, ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... at CareFirst Blue Cross BlueShield and Former Principal Deputy Administrator at Centers for ... an Anthem Company; Steve Ondra, MD, Chief Medical Officer at Health Care Service ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... injectables (LAIs), today announced a development collaboration with the Australian critical medicine ... mental disorders such as schizophrenia. , LAI medicines can offer improved therapeutic benefits ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term warfarin ... first offering the procedure in April of 2015, Florida Hospital Pepin Heart Institute ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... some macroalgae can use ultraviolet light A (UV-A) for photosynthesis, researchers Juntian Xu ... red, green, and brown seaweeds. The pair observed that when photosynthetically active radiation ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research ... the  "Europe Thrombocytopenia Market and Competitive ... their offering.       (Logo: ... latest research Europe Thrombocytopenia Market and ... comprehensive insights into Thrombocytopenia pipeline products, ...
(Date:5/4/2016)... -- Compass Diversified Holdings (NYSE: CODI ) ("CODI," ... middle market businesses, announced today its consolidated operating results ... First Quarter 2016 Highlights , Generated Cash ... Flow") of $13.6 million for the first quarter of ... for the first quarter of 2016; , Paid ...
(Date:5/4/2016)... Israel , May 4, 2016 ... BiondVax,s CEO, Dr. Ron Babecoff , will be attending ... York City . On Thursday, May 5, ... a conference presented by Joseph Gunner & Co, ... The BiondVax presentation that Dr. Babecoff will be using is ...
Breaking Medicine Technology: